The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma

A fundamental property of malignant tumors is increased glucose metabolism, which can be estimated by imaging the glucose analog fluorodeoxyglucose (FDG). The aim of this study was to determine whether FDG uptake in lung carcinoma, as measured on positron emission tomography (PET) imaging in patients with newly diagnosed bronchogenic carcinoma, has prognostic significance.

[1]  N. Gupta,et al.  Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose , 1994 .

[2]  M P Frick,et al.  Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. , 1993, Chest.

[3]  B. Johnson.  Biologic and molecular prognostic factors--impact on treatment of patients with non-small cell lung cancer. , 1995, Chest.

[4]  H. Nathan.  Management of solitary pulmonary nodules. An organized approach based on growth rate and statistics. , 1974, JAMA.

[5]  R. Wahl,et al.  Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. , 1994, Radiology.

[6]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[7]  S. Graziano.  Non-small cell lung cancer: clinical value of new biological predictors , 1997 .

[8]  V J Lowe,et al.  Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. , 1995, The Annals of thoracic surgery.

[9]  W. Weiss.  Tumor doubling time and survival of men with bronchogenic carcinoma. , 1974, Chest.

[10]  M. Gail,et al.  Prognostic factors in patients with resected stage I non‐small cell lung cancer. A report from the Lung Cancer Study Group , 1984, Cancer.

[11]  G. Silvestri,et al.  Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. , 1992, The American review of respiratory disease.

[12]  J. Sunderland,et al.  Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1992, Radiology.

[13]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[14]  R J Reitemeier,et al.  Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report , 1978, Cancer.

[15]  K E Stanley,et al.  Prognostic factors for survival in patients with inoperable lung cancer. , 1980, Journal of the National Cancer Institute.

[16]  Y. Ichinose,et al.  Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer ? A multivariate prognostic factor analysis of 151 patients. , 1993, The Journal of thoracic and cardiovascular surgery.

[17]  D. Harpole,et al.  Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence , 1995, Cancer.

[18]  R. Wahl,et al.  Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  P. Zimmerman,et al.  PLOIDY AS A PROGNOSTIC DETERMINANT IN SURGICALLY TREATED LUNG CANCER , 1987, The Lancet.

[20]  Y. Ichinose,et al.  Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer ? A multivariate prognostic factor analysis of 151 patients. , 1993, The Journal of thoracic and cardiovascular surgery.

[21]  Mark A. Stephenson,et al.  Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival , 1997, Cancer.

[22]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[23]  A. Sahin,et al.  Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. , 1991, The New England journal of medicine.

[24]  V. P. Collins,et al.  Differentiation of benign and malignant pulmonary nodules by growth rate. , 1962, Radiology.

[25]  P. Valk,et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. , 1995, The Annals of thoracic surgery.

[26]  T Ido,et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  T Ido,et al.  High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  A. Sakurada,et al.  Tumor doubling time and prognostic assessment of patients with primary lung cancer , 1994, Cancer.

[29]  J. Pater,et al.  Nonanatomic prognostic factors in carcinoma of the lung. A multivariate analysis , 1982, Cancer.

[30]  D. Sugarbaker,et al.  Screening for Lung Cancer: Another Look; A Different View , 1997 .

[31]  K. Inoue,et al.  Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non‐small cell lung cancer , 1990, Cancer.

[32]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[33]  G. Patterson,et al.  Immunostains for blood group antigens lack prognostic significance in T1 lung carcinoma. , 1995, The Annals of thoracic surgery.

[34]  R. Tsuchiya,et al.  Prognosis and survival in resected lung carcinoma based on the new international staging system. , 1988, The Journal of thoracic and cardiovascular surgery.

[35]  T. Tong,et al.  Cancer statistics, 1992 , 1992, CA: a cancer journal for clinicians.

[36]  V. P. Collins,et al.  Observations on growth rates of human tumors. , 1956, The American journal of roentgenology, radium therapy, and nuclear medicine.

[37]  G W Moore,et al.  Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung , 1984, The American journal of surgical pathology.

[38]  P. Buell,et al.  Asymptomatic solitary pulmonary nodules. Host survival, tumor size, and growth rate. , 1973, The Journal of thoracic and cardiovascular surgery.

[39]  Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. , 1993 .

[40]  S. Newsom,et al.  LOCAL CHEMOTHERAPY FOR PSEUDOMONAS LUNG ABSCESS , 1974 .

[41]  M Paesmans,et al.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  D. Geddes,et al.  The natural history of lung cancer: a review based on rates of tumour growth. , 1979, British journal of diseases of the chest.

[44]  D. Delbeke,et al.  Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. , 1996, Chest.